{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:43:52Z","timestamp":1792799032137,"version":"4.5.0"},"reference-count":76,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"unspecified","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"the Anhui Provincial Health Research Project","award":["2021sjlczdzk"],"award-info":[{"award-number":["2021sjlczdzk"]}]},{"name":"the Anhui Provincial Health Research Project","award":["AHWJ2023A20331"],"award-info":[{"award-number":["AHWJ2023A20331"]}]},{"name":"the Anhui Provincial Health Research Project","award":["AHWJ2024Aa20551"],"award-info":[{"award-number":["AHWJ2024Aa20551"]}]},{"name":"USTC Research Funds of the Double First-Class Initiative","award":["YD9100002056"],"award-info":[{"award-number":["YD9100002056"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82272301"],"award-info":[{"award-number":["82272301"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82472979"],"award-info":[{"award-number":["82472979"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Special Research Fund for Discipline Construction on Standardized Management of Myelosuppression, China Anti-Cancer Association","award":["CETSDCORP2772-37"],"award-info":[{"award-number":["CETSDCORP2772-37"]}]},{"name":"the Emerging Tumor Translational Medicine","award":["chmdf2025-xrky"],"award-info":[{"award-number":["chmdf2025-xrky"]}]},{"name":"the Strategic Priority Research Program of the Chinese Academy of Sciences","award":["XDB0940301"],"award-info":[{"award-number":["XDB0940301"]}],"id":[{"id":"https:\/\/ror.org\/034t30j35","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,5,20]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The immunologically \u201ccold\u201d microenvironment of triple-negative breast cancer presents a major obstacle to treatment, conferring resistance to current immunotherapies. Targeting the stimulator of interferon genes (STING) pathway has emerged as a promising strategy to enhance immunotherapy efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this preclinical study, we leveraged a novel integrated approach by employing a B7-H3-targeted dual-payload antibody-drug conjugate (ADC) to induce innate immune responses and reprogram the tumor microenvironment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our preliminary results indicated that the dual-payload ADC induces immunogenic cell death, leading to the release of double-stranded DNA and subsequent activation of the cyclic guanosine monophosphate-adenosine monophosphate (GMP-AMP) synthase-STING pathway in macrophages and dendritic cells. This, in turn, promotes dendritic cell maturation, M1 macrophage polarization, and enhanced T-cell infiltration, effectively converting immunologically \u201ccold\u201d tumors into \u201chot\u201d ones. Most importantly, the synergistic combination of the dual-payload ADC with immune checkpoint inhibitors (PD-L1 and 4\u20131BB) not only rapidly bridges innate and adaptive immunity but also elicits a robust long-term immune memory response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Collectively, these preliminary results demonstrate that the antitumor efficacy of the dual-payload ADC is mediated through STING pathway activation. This insight opens new avenues for enhancing immunotherapy in B7-H3-expressing solid tumors and paves the way for the clinical translation of next-generation ADC designs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-014392","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:15:17Z","timestamp":1780503317000},"page":"e014392","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Igniting cold tumors: reprogramming the tumor immune microenvironment with dual-payload ADCs in combination with PD-L1&amp;4-1BB bispecific antibodies"],"prefix":"10.1136","volume":"14","author":[{"given":"Jing","family":"Pan","sequence":"first","affiliation":[{"name":"Department of Breast Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China"},{"name":"Department of Medical Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China"},{"name":"Department of Medical Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Yu","sequence":"additional","affiliation":[{"name":"Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Liu","sequence":"additional","affiliation":[{"name":"College of life sciences, Wuhan University, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Shang","sequence":"additional","affiliation":[{"name":"Department of Research and Development, Anhui Genebiol Biotech. Ltd, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikai","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China"},{"name":"Department of Medical Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghua","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengzhi","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China"},{"name":"Department of Medical Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengchuan","family":"Jin","sequence":"additional","affiliation":[{"name":"Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China"},{"name":"Department of Infectious Diseases, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, University of Science and Technology of China, Hefei, Anhui, China"},{"name":"Biomedical Sciences and Health Laboratory of Anhui Province, University of Science & Technology of China, Hefei, Anhui, China"},{"name":"Clinical Research Hospital of Chinese Academy of Sciences (Hefei), University of Science and Technology of China, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyin","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1080-7396","authenticated-orcid":false,"given":"Shoubing","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China"},{"name":"Department of Medical Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"2026060309150744000_14.6.e014392.1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cac2.12539","article-title":"Immunologic tumor microenvironment modulators for turning cold tumors hot","volume":"44","author":"Khosravi","year":"2024","journal-title":"Cancer Commun"},{"key":"2026060309150744000_14.6.e014392.2","doi-asserted-by":"crossref","first-page":"114319","DOI":"10.1016\/j.jconrel.2025.114319","article-title":"Oxygen-vacancy MoO3-x nanodots induce immunogenic cell death and STING activation for synergistic cancer immunotherapy","volume":"388","author":"Hang","year":"2025","journal-title":"J Control Release"},{"key":"2026060309150744000_14.6.e014392.3","doi-asserted-by":"crossref","first-page":"2413289","DOI":"10.1002\/adma.202413289","article-title":"Cryo\u2010Shocked Tumor\u2010Reprogrammed Sonosensitive Antigen\u2010Presenting Cells Improving Sonoimmunotherapy via T Cells and NK Cells Immunity","volume":"37","author":"Qian","year":"2025","journal-title":"Adv Mater Weinheim"},{"key":"2026060309150744000_14.6.e014392.4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41420-025-02682-8","article-title":"Empowering hypoxia to convert cold tumors into hot tumors for breast cancer immunotherapy","volume":"11","author":"Liu","year":"2025","journal-title":"Cell Death Discov"},{"key":"2026060309150744000_14.6.e014392.5","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1158\/0008-5472.CAN-24-0707","article-title":"Ribosomal RNA Biosynthesis Functionally Programs Tumor-Associated Macrophages to Support Breast Cancer Progression","volume":"85","author":"Metge","year":"2025","journal-title":"Cancer Res"},{"key":"2026060309150744000_14.6.e014392.6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/0471142735.im1400s93","article-title":"Innate Immunity","volume":"93","author":"Coligan","year":"2011","journal-title":"CP Immunol"},{"key":"2026060309150744000_14.6.e014392.7","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-025-02380-0","article-title":"Demystifying the cGAS-STING pathway: precision regulation in the tumor immune microenvironment","volume":"24","author":"Wang","year":"2025","journal-title":"Mol Cancer"},{"key":"2026060309150744000_14.6.e014392.8","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adu6989","article-title":"Sequential treatment with PARPi and WEE1i enhances antitumor immune responses in preclinical models of ovarian cancer","volume":"17","author":"Jiao","year":"2025","journal-title":"Sci Transl Med"},{"key":"2026060309150744000_14.6.e014392.9","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1021\/acscentsci.4c00579","article-title":"STING-Activating Polymer-Drug Conjugates for Cancer Immunotherapy","volume":"10","author":"Sheehy","year":"2024","journal-title":"ACS Cent Sci"},{"key":"2026060309150744000_14.6.e014392.10","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1016\/j.molcel.2025.08.030","article-title":"Activation and regulation of cGAS-STING signaling in cancer cells","volume":"85","author":"Shim","year":"2025","journal-title":"Mol Cell"},{"key":"2026060309150744000_14.6.e014392.11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s13046-025-03520-6","article-title":"Targeting the interplay of cGAS-STING and ferroptosis by nanomedicine in the treatment of cancer","volume":"44","author":"Li","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"2026060309150744000_14.6.e014392.12","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-025-00750-w","article-title":"Targeting cGAS-STING pathway for reprogramming tumor-associated macrophages to enhance anti-tumor immunotherapy","volume":"13","author":"Zhang","year":"2025","journal-title":"Biomark Res"},{"key":"2026060309150744000_14.6.e014392.13","first-page":"450","article-title":"Mitochondria-targeted MXene@MnO2-TPP nanoheterostructures for synergistic enhancement of sonodynamic therapy and immunotherapy in osteosarcoma","volume":"54","author":"Zeng","year":"2025","journal-title":"Bioact Mater"},{"key":"2026060309150744000_14.6.e014392.14","doi-asserted-by":"crossref","first-page":"113565","DOI":"10.1016\/j.jconrel.2025.02.061","article-title":"STING pathway activation with cisplatin polyprodrug nanoparticles for chemo-immunotherapy in ovarian cancer","volume":"381","author":"Fu","year":"2025","journal-title":"J Control Release"},{"key":"2026060309150744000_14.6.e014392.15","doi-asserted-by":"crossref","first-page":"2408086","DOI":"10.1002\/advs.202408086","article-title":"GRP78 Nanobody\u2010Directed Immunotoxin Activates Innate Immunity Through STING Pathway to Synergize Tumor Immunotherapy","volume":"12","author":"Wang","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"2026060309150744000_14.6.e014392.16","doi-asserted-by":"crossref","first-page":"161735","DOI":"10.1016\/j.cej.2025.161735","article-title":"Biomimetic nanoadjuvant-enhanced ultrasound-induced STING activation potentiates aPD-L1 therapy to overcome cancer recurrence and metastasis","volume":"511","author":"Yang","year":"2025","journal-title":"Chem Eng J"},{"key":"2026060309150744000_14.6.e014392.17","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.chembiol.2025.01.004","article-title":"An oral tricyclic STING agonist suppresses tumor growth through remodeling of the immune microenvironment","volume":"32","author":"Zhao","year":"2025","journal-title":"Cell Chem Biol"},{"key":"2026060309150744000_14.6.e014392.18","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-023-00551-z","article-title":"Nanomaterial-encapsulated STING agonists for immune modulation in cancer therapy","volume":"12","author":"Chen","year":"2024","journal-title":"Biomark Res"},{"key":"2026060309150744000_14.6.e014392.19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-025-01691-5","article-title":"The cGAS\u2012STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications","volume":"18","author":"Shen","year":"2025","journal-title":"J Hematol Oncol"},{"key":"2026060309150744000_14.6.e014392.20","doi-asserted-by":"crossref","first-page":"113667","DOI":"10.1016\/j.jconrel.2025.113667","article-title":"Breaking the barriers in effective and safe Toll-like receptor stimulation via nano-immunomodulators for potent cancer immunotherapy","volume":"382","author":"Li","year":"2025","journal-title":"J Control Release"},{"key":"2026060309150744000_14.6.e014392.21","doi-asserted-by":"crossref","first-page":"107969","DOI":"10.1016\/j.phrs.2025.107969","article-title":"Unveiling the potential of natural TLR modulators in cancer immunotherapy","volume":"221","author":"Zheng","year":"2025","journal-title":"Pharmacol Res"},{"key":"2026060309150744000_14.6.e014392.22","doi-asserted-by":"crossref","unstructured":"Xing Y , Wu R , Tu Z , et al . Precisely deliver toll-like receptor agonists using a dual-responsive nanovaccine for effective cancer immunotherapy. Biomaterials 2026;324. doi:10.1016\/j.biomaterials.2025.123527","DOI":"10.1016\/j.biomaterials.2025.123527"},{"key":"2026060309150744000_14.6.e014392.23","doi-asserted-by":"crossref","first-page":"34659","DOI":"10.1021\/jacs.5c09791","article-title":"An Activatable and Covalent Tumor-Associated Antigen Capturer Enabling Systemic Injection In Vivo for Promoted Antitumor Immunity","volume":"147","author":"Gao","year":"2025","journal-title":"J Am Chem Soc"},{"key":"2026060309150744000_14.6.e014392.24","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1021\/acs.accounts.0c00337","article-title":"Chemical Strategies to Enhance the Therapeutic Efficacy of Toll-like Receptor Agonist Based Cancer Immunotherapy","volume":"53","author":"Lee","year":"2020","journal-title":"Acc Chem Res"},{"key":"2026060309150744000_14.6.e014392.25","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat Commun"},{"key":"2026060309150744000_14.6.e014392.26","doi-asserted-by":"crossref","unstructured":"Zhang J-Q , Zhang N , Ran Y , et al . Computation-driven discovery of novel chromone derivatives for the treatment of triple-negative breast cancer via mTOR-targeted inhibition and triggering antitumor immunity. Acta Pharm Sin B 2025. doi:10.1016\/j.apsb.2025.09.010","DOI":"10.1016\/j.apsb.2025.09.010"},{"key":"2026060309150744000_14.6.e014392.27","doi-asserted-by":"crossref","unstructured":"Wan M , Mei J , Cai Y , et al . Targeting IGF1R Overcomes Armored and Cold Tumor Microenvironment and Boosts Immune Checkpoint Blockade in Triple\u2010Negative Breast Cancer. Adv Sci (Weinh) 2025;12. doi:10.1002\/advs.202501341","DOI":"10.1002\/advs.202501341"},{"key":"2026060309150744000_14.6.e014392.28","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg0289","article-title":"A transcriptome-informed QSP model of metastatic triple-negative breast cancer identifies predictive biomarkers for PD-1 inhibition","volume":"9","author":"Arulraj","year":"2023","journal-title":"Sci Adv"},{"key":"2026060309150744000_14.6.e014392.29","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202501341","article-title":"Targeting IGF1R Overcomes Armored and Cold Tumor Microenvironment and Boosts Immune Checkpoint Blockade in Triple\u2010Negative Breast Cancer","volume":"12","author":"Wan","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"2026060309150744000_14.6.e014392.30","first-page":"61","article-title":"Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of postoperative \u201ccold\u201d triple-negative breast cancer","volume":"25","author":"Guo","year":"2023","journal-title":"Bioact Mater"},{"key":"2026060309150744000_14.6.e014392.31","doi-asserted-by":"crossref","first-page":"14877","DOI":"10.1021\/acsnano.3c08425","article-title":"Syringeable Near-Infrared Light-Activated In Situ Immunogenic Hydrogel Boosts the Cancer-Immunity Cycle to Enhance Anticancer Immunity","volume":"18","author":"Fu","year":"2024","journal-title":"ACS Nano"},{"key":"2026060309150744000_14.6.e014392.32","doi-asserted-by":"crossref","first-page":"166083","DOI":"10.1016\/j.cej.2025.166083","article-title":"Genetically engineered bacteria outer membrane vesicles coated small-molecule organic dye facilitates cDC1s-mediated antitumor immune cascade response for NIR-II tumor photoimmunotheranostics","volume":"520","author":"Chen","year":"2025","journal-title":"Chem Eng J"},{"key":"2026060309150744000_14.6.e014392.33","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1016\/j.apsb.2025.04.006","article-title":"Targeting stem-property and vasculogenic mimicry for sensitizing paclitaxel therapy of triple-negative breast cancer by biomimetic codelivery","volume":"15","author":"Wu","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"2026060309150744000_14.6.e014392.34","doi-asserted-by":"crossref","first-page":"217685","DOI":"10.1016\/j.canlet.2025.217685","article-title":"A high-affinity antibody-drug conjugates Actuximab-MMAE for potent and selective targeting of CEACAM5-Positive tumors","volume":"620","author":"Hu","year":"2025","journal-title":"Cancer Lett"},{"key":"2026060309150744000_14.6.e014392.35","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41591-025-03600-2","article-title":"A B7H3-targeting antibody\u2013drug conjugate in advanced solid tumors: a phase 1\/1b trial","volume":"31","author":"Ma","year":"2025","journal-title":"Nat Med"},{"key":"2026060309150744000_14.6.e014392.36","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adq0513","article-title":"Targeting uPAR with an antibody-drug conjugate suppresses tumor growth and reshapes the immune landscape in pancreatic cancer models","volume":"11","author":"Metrangolo","year":"2025","journal-title":"Sci Adv"},{"key":"2026060309150744000_14.6.e014392.37","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011533","article-title":"B7-H3 and CSPG4 co-targeting as Pan-CAR-T cell treatment of triple-negative breast cancer","volume":"13","author":"Stucchi","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026060309150744000_14.6.e014392.38","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrp.2025.102723","article-title":"A zirconium-89-labeled antibody-drug conjugate PET probe for noninvasive monitoring of Nectin4 expression in breast cancer and lung cancer","volume":"6","author":"Huang","year":"2025","journal-title":"Cell Rep Phys Sci"},{"key":"2026060309150744000_14.6.e014392.39","doi-asserted-by":"crossref","first-page":"217906","DOI":"10.1016\/j.canlet.2025.217906","article-title":"Preserved host immunity with intercellular adhesion molecule-1 (ICAM-1)-targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of triple-negative breast cancer and other malignancies","volume":"630","author":"Takao","year":"2025","journal-title":"Cancer Lett"},{"key":"2026060309150744000_14.6.e014392.40","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3361"},{"key":"2026060309150744000_14.6.e014392.41","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1200\/JCO.2021.39.15_suppl.2631","article-title":"Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors","volume":"39","author":"Jang","year":"2021","journal-title":"JCO"},{"key":"2026060309150744000_14.6.e014392.42","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01751-9","article-title":"New frontiers in immune checkpoint B7-H3 (CD276) research and drug development","volume":"22","author":"Getu","year":"2023","journal-title":"Mol Cancer"},{"key":"2026060309150744000_14.6.e014392.43","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.trecan.2025.02.007","article-title":"Targeting novel immune checkpoints in the B7-H family: advancing cancer immunotherapy from bench to bedside","volume":"11","author":"Luo","year":"2025","journal-title":"Trends Cancer"},{"key":"2026060309150744000_14.6.e014392.44","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011370","article-title":"Novel trispecific killer engager targeting B7-H3 enhances natural killer cell antitumor activity against head and neck cancer","volume":"13","author":"Khaw","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026060309150744000_14.6.e014392.45","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.tips.2025.08.008","article-title":"The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics","volume":"46","author":"Corrigan","year":"2025","journal-title":"Trends Pharmacol Sci"},{"key":"2026060309150744000_14.6.e014392.46","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaf193.123","article-title":"P01.43.A PD-L1 and B7-H3 checkpoint inhibitor blockade in glioblastoma","volume":"27","author":"Knight","year":"2025","journal-title":"Neuro-Oncol"},{"key":"2026060309150744000_14.6.e014392.47","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007174","article-title":"Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma","volume":"11","author":"Brignole","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026060309150744000_14.6.e014392.48","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-25-A140","article-title":"Abstract A140: MGC026, a glycan-linked, exatecan-based antibody-drug conjugate (ADC) targeting B7-H3, is efficacious toward prostate cancer patient-derived xenografts","volume":"24","author":"Scribner","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"2026060309150744000_14.6.e014392.49","doi-asserted-by":"crossref","first-page":"2415577","DOI":"10.1002\/advs.202415577","article-title":"Reprogramming the Tumor Immune Microenvironment with ICAM\u20101\u2010Targeted Antibody\u2012Drug Conjugates and B7\u2010H3\u2010CD3 Bispecific Antibodies","volume":"12","author":"Zhou","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"2026060309150744000_14.6.e014392.50","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1494206","article-title":"Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation","volume":"15","author":"Hangiu","year":"2024","journal-title":"Front Immunol"},{"key":"2026060309150744000_14.6.e014392.51","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.1133","article-title":"1075TiP A phase I trial of ATG-101, an investigational PD-L1\u00d74-1BB bispecific antibody, in patients with advanced solid tumors and mature B cell non-Hodgkin lymphomas: PROBE-CN","volume":"35","author":"Xue","year":"2024","journal-title":"Ann Oncol"},{"key":"2026060309150744000_14.6.e014392.52","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-27613-w","article-title":"CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation","volume":"12","author":"Otano","year":"2021","journal-title":"Nat Commun"},{"key":"2026060309150744000_14.6.e014392.53","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-21-1345","article-title":"Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors","volume":"12","author":"Muik","year":"2022","journal-title":"Cancer Discov"},{"key":"2026060309150744000_14.6.e014392.54","doi-asserted-by":"crossref","unstructured":"Mowat C , Mosley SR , Namdar A , et al . Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN\u2013driven CCL5 and CXCL10. J Exp Med 2021;218. doi:10.1084\/jem.20210108","DOI":"10.1084\/jem.20210108"},{"key":"2026060309150744000_14.6.e014392.55","doi-asserted-by":"crossref","unstructured":"Dong M , Xue C , Yang X , et al . Self\u2010Propelled Bacteria\u2010Mediated In Situ Biosynthesis of MnS Nanoparticles for Remodeling Tumor Microenvironment to Amplify cGAS\u2010STING Pathway for Antitumor Immunity. Adv Funct Materials 2025;35. doi:10.1002\/adfm.202503733","DOI":"10.1002\/adfm.202503733"},{"key":"2026060309150744000_14.6.e014392.56","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-025-02489-2","article-title":"Antibody\u2013drug conjugates in cancer therapy: current landscape, challenges, and future directions","volume":"24","author":"Chen","year":"2025","journal-title":"Mol Cancer"},{"key":"2026060309150744000_14.6.e014392.57","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1158\/1535-7163.MCT-24-0649","article-title":"The Anti-FR\u03b1 Antibody-Drug Conjugate Luveltamab Tazevibulin Demonstrates Efficacy in Non-Small Cell Lung Cancer Preclinical Models and Induces Immunogenic Cell Death","volume":"24","author":"Yuan","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"2026060309150744000_14.6.e014392.58","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1158\/1538-7445.AM2025-1805","article-title":"Abstract 1805: Dual-payload TME-activated ADC platform","volume":"85","author":"Liu","year":"2025","journal-title":"Cancer Res"},{"key":"2026060309150744000_14.6.e014392.59","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1021\/acsmedchemlett.5c00209","article-title":"Homogeneous Dual-Payload Antibody-Drug Conjugates Produced by Combined Distinct Conjugation Strategies","volume":"16","author":"Watanabe","year":"2025","journal-title":"ACS Med Chem Lett"},{"key":"2026060309150744000_14.6.e014392.60","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1158\/1538-7445.AM2025-1586","article-title":"Abstract 1586: KH815, a novel dual-payload TROP2-directed antibody-drug conjugate, shows potent antitumor efficacy in pre-clinical tumor model","volume":"85","author":"Zhao","year":"2025","journal-title":"Cancer Res"},{"key":"2026060309150744000_14.6.e014392.61","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1158\/2159-8290.CD-22-0837","article-title":"Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis","volume":"12","author":"Jerusalem","year":"2022","journal-title":"Cancer Discov"},{"key":"2026060309150744000_14.6.e014392.62","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s40364-024-00633-6","article-title":"Trop2-targeted therapy in breast cancer","volume":"12","author":"Hu","year":"2024","journal-title":"Biomark Res"},{"key":"2026060309150744000_14.6.e014392.63","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s12032-024-02542-y","article-title":"Understanding the chemistry & pharmacology of antibody-drug conjugates in triple-negative breast cancer with special reference to exatecan derivatives","volume":"41","author":"Sawant","year":"2024","journal-title":"Med Oncol"},{"key":"2026060309150744000_14.6.e014392.64","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1158\/1538-7445.AM2025-2874","article-title":"Abstract 2874: ZW327, a novel Ly6E-targeting antibody-drug conjugate bearing a topoisomerase 1 inhibitor payload","volume":"85","author":"Urosev","year":"2025","journal-title":"Cancer Res"},{"key":"2026060309150744000_14.6.e014392.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2020.01.003"},{"key":"2026060309150744000_14.6.e014392.66","doi-asserted-by":"crossref","first-page":"113333","DOI":"10.1016\/j.eurpolymj.2024.113333","article-title":"Polysaccharide nanoadjuvants with precise drug composition for enhanced STING-mediated APC activation","volume":"217","author":"Ju","year":"2024","journal-title":"Eur Polym J"},{"key":"2026060309150744000_14.6.e014392.67","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2004661","article-title":"Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade","volume":"10","author":"Warmuth","year":"2021","journal-title":"Oncoimmunology"},{"key":"2026060309150744000_14.6.e014392.68","doi-asserted-by":"crossref","DOI":"10.1186\/s11658-023-00461-w","article-title":"An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity","volume":"28","author":"Cheng","year":"2023","journal-title":"Cell Mol Biol Lett"},{"key":"2026060309150744000_14.6.e014392.69","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1021\/acs.bioconjchem.5c00424","article-title":"Identification of a Novel Linker Enabling the Bioconjugation of a Cyclic Dinucleotide for the STING Antibody-Drug Conjugate TAK-500","volume":"36","author":"Lee","year":"2025","journal-title":"Bioconjug Chem"},{"key":"2026060309150744000_14.6.e014392.70","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-49932-4","article-title":"Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses","volume":"15","author":"Malli Cetinbas","year":"2024","journal-title":"Nat Commun"},{"key":"2026060309150744000_14.6.e014392.71","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1158\/1538-7445.AM2025-3407","article-title":"Abstract 3407: Development of bispecific antibodies targeting claudin-6 for precision cancer therapy","volume":"85","author":"Tahk","year":"2025","journal-title":"Cancer Res"},{"key":"2026060309150744000_14.6.e014392.72","doi-asserted-by":"crossref","unstructured":"Liu J , Deng Y , Pu Z , et al . The AURKA inhibitor alters the immune microenvironment and enhances targeting B7-H3 immunotherapy in glioblastoma. JCI Insight 2025;10. doi:10.1172\/jci.insight.173700","DOI":"10.1172\/jci.insight.173700"},{"key":"2026060309150744000_14.6.e014392.73","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009710","article-title":"Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses","volume":"12","author":"Dong","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026060309150744000_14.6.e014392.74","doi-asserted-by":"crossref","unstructured":"Sharma S , Mundhara N , Tekoglu E , et al . B7-h3 as a dual clinically relevant checkpoint and antibody drug conjugate target expressed across adenocarcinoma and neuroendocrine prostate cancers. Cancer Biol 2025. doi:10.1101\/2025.01.21.632253","DOI":"10.1101\/2025.01.21.632253"},{"key":"2026060309150744000_14.6.e014392.75","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1158\/1538-7445.AM2025-3499","article-title":"Abstract 3499: Engineering and construction of anti-B7-H3 antibody-based T cell engagers (TCEs) and antibody-drug conjugates (ADCs) for cancer therapy","volume":"85","author":"Chen","year":"2025","journal-title":"Cancer Res"},{"key":"2026060309150744000_14.6.e014392.76","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1158\/1538-7445.AM2025-830","article-title":"Abstract 830: Combined a B7-H3-targeting antibody-drug conjugate, 7MW3711, and PARP inhibitors synergistically potentiates the antitumor activity in B7-H3-positive cancers","volume":"85","author":"Cen","year":"2025","journal-title":"Cancer Res"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:15:28Z","timestamp":1780503328000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":76,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,3]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/jitc-2025-014392"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014392","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}